Abstract
Alzheimers disease is an age-related neurodegenerative disease which causes global loss of cognitive function. Drug treatment for Alzheimers disease has been limited to agents that ameliorate behavioral symptoms but these agents are without effect on disease progression. Rational drug design for the treatment of Alzheimers disease now seems possible. As a result of major advances in medical research in this area, knowledge of the etiology of Alzheimers disease is rapidly being understood. This information has uncovered relevant and novel targets for treatment. At the center of the etiological progression of this disease is β-amyloid. A substantial body of evidence strongly suggests that this small protein is critical to the development of Alzheimers disease. The β-amyloid protein is generated by two different proteolytic cleavages. Recently, the proteases responsible for producing the β-amyloid protein have been identified. The proteases represent viable targets for therapeutic intervention against Alzheimers disease. In this review, we describe the biological characteristics of the β-amyloid-forming proteases in the context of pharmaceutical development.
Keywords: Amyloid, Proteases, Alzheimers Disease
Current Pharmaceutical Design
Title: Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease
Volume: 8 Issue: 28
Author(s): Frauke Schimmoller, Jeffrey N. Higaki and Barbara Cordell
Affiliation:
Keywords: Amyloid, Proteases, Alzheimers Disease
Abstract: Alzheimers disease is an age-related neurodegenerative disease which causes global loss of cognitive function. Drug treatment for Alzheimers disease has been limited to agents that ameliorate behavioral symptoms but these agents are without effect on disease progression. Rational drug design for the treatment of Alzheimers disease now seems possible. As a result of major advances in medical research in this area, knowledge of the etiology of Alzheimers disease is rapidly being understood. This information has uncovered relevant and novel targets for treatment. At the center of the etiological progression of this disease is β-amyloid. A substantial body of evidence strongly suggests that this small protein is critical to the development of Alzheimers disease. The β-amyloid protein is generated by two different proteolytic cleavages. Recently, the proteases responsible for producing the β-amyloid protein have been identified. The proteases represent viable targets for therapeutic intervention against Alzheimers disease. In this review, we describe the biological characteristics of the β-amyloid-forming proteases in the context of pharmaceutical development.
Export Options
About this article
Cite this article as:
Schimmoller Frauke, Higaki N. Jeffrey and Cordell Barbara, Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease, Current Pharmaceutical Design 2002; 8 (28) . https://dx.doi.org/10.2174/1381612023392658
DOI https://dx.doi.org/10.2174/1381612023392658 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Editorial: Statins and Tissue Plasminogen Activator for Stroke: A Beneficial Combination?
Current Vascular Pharmacology Cardiovascular Disease in the Rheumatic Diseases: How Systemic Inflammation May Contribute to Atherogenesis
Current Rheumatology Reviews Posaconazole: A New Antifungal Weapon
Reviews on Recent Clinical Trials Medical Complications in Anorexia and Bulimia Nervosa
Endocrine, Metabolic & Immune Disorders - Drug Targets Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology Obstructive Sleep Apnea as an Independent Stroke Risk Factor: Possible Mechanisms
Current Molecular Medicine Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Biophysical Characterization of the Membrane-proximal Ectodomain of the Receptor-type Protein-tyrosine Phosphatase Phogrin
Protein & Peptide Letters Emerging Concepts in Diabetes: Mitochondrial Dynamics and Glucose Homeostasis
Current Diabetes Reviews Recent Research Progress in Natural Bioactive Constituents against Lipid Metabolic Diseases
Current Topics in Medicinal Chemistry The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics 2-Mercapto Benzothiazole Derivatives: As Potential Leads for the Diabetic Management
Medicinal Chemistry Molecular Based Drug Targets for Idiopathic Pulmonary Fibrosis
Current Respiratory Medicine Reviews The Role of Polyunsaturated Fatty Acids (PUFA) in the Treatment of Dyslipidemias
Current Pharmaceutical Design Synthesis, Docking and Evaluation of Phenylacetic Acid and Trifluoro-methylphenyl Substituted Benzamide Derivatives as Potential PPARδ Agonists
Letters in Drug Design & Discovery MicroRNAs and Physical Activity
MicroRNA Effects of Maternal Obesity On Placental Phenotype
Current Vascular Pharmacology Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat
Current Vascular Pharmacology